PDF factsheet
      Z

prevention in atrial fibrillation for patients without history of AF (primary prevention), clinical trials results

atorvastatin versus placebo
MIRACL (AF ancillary study), 2001
atorvastatin 80mg daily
versus
placebo
Acute coronary syndrome; subgroup without history of AFdouble-blind
Follow-up duration: 16 weeks
Chello, 2006
atorvastatin 20mg daily
versus
placebo
patients with scheduled coronary bypass surgerydouble-blind
Follow-up duration: 3 weeks
ARMYDA-3 (AF ancillary study), 2006
atorvastatin 40mg daily
versus
placebo
patients with scheduled cardiac surgery without history of AF
Follow-up duration: 30 days
candesartan versus placebo
CHARM (AF ancillary study), 2005
candesartan
versus
placebo
Heart failure
Follow-up duration: 3.17 y
enalapril versus placebo
SOLVD (AF ancillary study), 2003
enalapril
versus
placebo
Heart failure
Follow-up duration: 2.9 y
gemfibrozil versus placebo
VA HIT (AF ancillary study), 1999
gemfibrozil
versus
placebo
men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or lessdouble blind
Follow-up duration: 4.4 y
US
lisinopril versus placebo
GISSI-3 (AF ancillary study), 2003
lisinopril
versus
placebo
Post–myocardial infarction
Follow-up duration: 0.5 y
losartan versus atenolol
LIFE (AF ancillary study), 2005
losartan
versus
atenolol
hypertension
Follow-up duration: 4.8 y
rosuvastatin versus placebo
GISSI HF (subgroup and ancillary study), 2009
NCT00336336
rosuvastatin 10mg daily
versus
placebo
patients with chronic heart failure who were not in AF at study entrydouble-blind
Follow-up duration: 3.7y (median)
Italy
trandolapril versus placebo
TRACE (AF ancillary study), 1999
trandolapil
versus
placebo
Post–myocardial infarction
Follow-up duration: 2.4 y
valsartan versus placebo
Val-HeFT (AF ancillary study), 2003
valsartan
versus
placebo
Heart failure
Follow-up duration: 1.92 y

  Options


in first

in second

  Filter